CYP2C19 and coronary artery disorder: Similarly, it was reported in a study using stable coronary artery disease patients that approximately 18–25% of the CYP2C19 *1/ *1 carriers and 38–43% of the CYP2C19 *1/ *2 carriers demonstrated high platelet reactivity following clopidogrel administration [25].